Literature DB >> 10630195

Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer.

A Ghodsi1, C Stein, T Derksen, I Martins, R D Anderson, B L Davidson.   

Abstract

Mucopolysaccharidosis VII, a classical lysosomal storage disease, is caused by deficiency of the enzyme beta-glucuronidase. Central nervous system (CNS) manifestations are severe with accumulations of storage vacuoles in all cell types. Intraventricular gene transfer can lead to transduction of the ependyma, with production and secretion of beta-glucuronidase into the cerebral spinal fluid and underlying cortex resulting in reversal of disease pathology restricted to the periventricular areas. We tested if systemic hyperosmolality would increase the distribution of beta-glucuronidase in brain parenchyma after intraventricular virus injection. Mice were administered mannitol, intraperitoneally, 20 days after gene transfer and 1 day prior to sacrifice. Mannitol-induced systemic hyperosmolality caused a marked penetration of beta-glucuronidase into the brain parenchyma. If mannitol was administered at the time of the intraventricular injection of virus, there was penetration of vector across the ependymal cell layer, with infection of cells in the subependymal region. This also resulted in increased beta-glucuronidase activity throughout the brain. Sections of brains from beta-glucuronidase-deficient mice showed correction of cellular pathology in the subependymal region plus cortical structures away from the ventricular wall. These data indicate that virus-mediated gene transfer to the brain via the ventricles, coupled with systemic mannitol administration, can lead to extensive CNS distribution of beta-glucuronidase with concomitant correction of the storage defect. Our findings have positive therapeutic implications for the treatment of CNS disorders with gene transfer vectors and recombinant proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630195     DOI: 10.1006/exnr.1999.7205

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  22 in total

1.  Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector.

Authors:  M A Passini; J H Wolfe
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 2.  Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.

Authors:  William S Sly; Carole Vogler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

Review 3.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

4.  FGF-2 regulation of neurogenesis in adult hippocampus after brain injury.

Authors:  S Yoshimura; Y Takagi; J Harada; T Teramoto; S S Thomas; C Waeber; J C Bakowska; X O Breakefield; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 5.  Gene therapy for mucopolysaccharidosis.

Authors:  Katherine P Ponder; Mark E Haskins
Journal:  Expert Opin Biol Ther       Date:  2007-09       Impact factor: 4.388

6.  Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice.

Authors:  Shervin Gholizadeh; Sujeenthar Tharmalingam; Margarita E Macaldaz; David R Hampson
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

7.  A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna.

Authors:  Toloo Taghian; Miklos G Marosfoi; Ajit S Puri; Oguz I Cataltepe; Robert M King; Elise B Diffie; Anne S Maguire; Douglas R Martin; Deborah Fernau; Ana Rita Batista; Tim Kuchel; Chris Christou; Raj Perumal; Sundeep Chandra; Paul D Gamlin; Stephanie G Bertrand; Terence R Flotte; Diane McKenna-Yasek; Phillip W L Tai; Neil Aronin; Matthew J Gounis; Miguel Sena-Esteves; Heather L Gray-Edwards
Journal:  Mol Ther       Date:  2019-11-16       Impact factor: 11.454

8.  Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice.

Authors:  W S Sly; C Vogler; J H Grubb; M Zhou; J Jiang; X Y Zhou; S Tomatsu; Y Bi; E M Snella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 9.  Therapeutic gene transfer to the nervous system using viral vectors.

Authors:  Joseph C Glorioso; Marina Mata; David J Fink
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

10.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.